Photopheresis in Early-stage Mycosis Fungoides
Plain-language summary
This trial is testing UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis for patients with cutaneous T-cell lymphoma (CTCL), including mycosis fungoides or Sézary syndrome whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. Researchers want to learn whether this approach can help control the lymphoma. This trial is available at 1 location in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis (DRUG): Extracorporeal Photopheresis (ECP) | THERAKOS® CELLEX photopheresis system (DEVICE): THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis, THERAKOS® CELLEX photopheresis system
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details